CUE News and Press, Cue Biopharma Inc. From 05/11/22

Shares of Cue Biopharma have tumbled some 75% since November 2021, as somewhat underwhelming data from slowly developing Phase 1 trials are at fault. The company’s Immuno-STAT platform is a novel approach to immuno-oncology that should reduce risks associated with systemic expo...

The U.S. FDA has accepted an Investigational New Drug application from Cue Biopharma (NASDAQ:CUE) for CUE-102, under investigation initially for gastric, pancreatic, ovarian and colon cancers. CUE-102 is designed to treat Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers, an onco-fet...

Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancers Starting dose of 1 mg/kg expected to reduce time and cost of dose escalation phase of trial, supporting development efficiency o...

Cue Biopharma press release (NASDAQ:CUE): Q1 GAAP EPS of -$0.44 misses by $0.02. Revenue of $1M (-35.5% Y/Y) misses by $1.92M. For further details see: Cue Biopharma GAAP EPS of -$0.44 misses by $0.02, revenue of $1M misses by $1.92M

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, today reported first qua...

Shares of Cue Biopharma Inc. (NASDAQ:CUE) traded today at $35.20, eclipsing its 52-week high. So far today approximately 17.4 million shares have been exchanged, as compared to an average 30-day volume of 573,000 shares. There is potential upside of 5.8% for shares of Cue Biopharma Inc. ...

Clinical-stage biotech, Cue Biopharma (CUE +7.1%), is trading higher for the fourth straight session on Tuesday after its director Aaron Fletcher disclosed an insider purchase worth millions of dollars. According to a Form 4 filed with the U.S. Securities and Exchange Commission (SEC) on Mond...

Gainers: Sunshine Biopharma (SBFM) +181%. Nano-X Imaging (NNOX) +15%. Arcus Biosciences (RCUS) +13%. Cue Biopharma (CUE) +11%. Dermata Therapeutics (DRMA) +6%. Losers: IMARA (IMRA) -35%. GBS (GBS) -15%. Precipio (PRPO) -13%. Cassava Sciences (SAVA) -10%...

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced to...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...